> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# FDA Sees ‘Challenges’ in Condoliase BLA
- URL: https://www.fdaweb.com/fda-sees-challenges-in-condoliase-bla/
- Published: 2025-01-08T12:00:00.000Z
- Updated: 2026-09-14T14:50:23.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5158453

The FDA Anesthetic and Analgesic Drug Products Advisory Committee will discuss 1/10 the challenges FDA has identified in a Seikagaku BLA for condoliase with a proposed indication to treat radicular leg pain associated with confirmed nerve root impingement caused by lumbar disc herniation in adults. An agency [briefing document](https://www.fda.gov/media/184938/download?ref=fdaweb.com) circulated in advance of the meeting identifies these challenges for the committee to consider:

- the relevance of one negative adequate and well-controlled trial in the context of two positive trials;
- the identification of patients most appropriate for condoliase;
- the significance of increased axial back pain and spine-related adverse events due to the product mechanism of action;
- the appropriate proceduralist and procedure setting requirements to ensure safe intradiscal administration and aftercare for condoliase injection; and
- concern for immune-related adverse events, including hypersensitivity reactions, anaphylaxis, and the risk of severe cutaneous adverse reactions, and corresponding mitigation and/or monitoring strategies.

Condoliase is described as an enzyme purified from a Gram-negative bacillus (*Proteus vulgaris*) that degrades chondroitin sulfate that, in its hydrated state, comprises most of the volume of the nucleus pulposus of the intervertebral disc. The document says the company proposes to market condoliase for injection into a herniated intervertebral disc to decrease disc volume, reduce herniation, and relieve impingement of the affected spinal nerve root, with the intent of decreasing radicular leg pain.

Committee members are asked to consider these points in preparing for the meeting:

- comment on the significance of the negative study in the context of the other two positive studies for establishing the drug’s efficacy;
- discuss key elements to be included in prescribing information to help clinicians identify patients who would have a favorable benefit/risk profile if treated with condoliase;
- discuss whether the benefits of the drug mechanism to reduce radicular leg pain (disc volume reduction as a means to alleviate nerve impingement) outweigh the potential short- and long-term adverse effects of increased axial back pain and altered spine anatomy;
- given the route of administration, the narrow population in which the drug has been established to be effective, and the potential risks of both the product and the procedure, discuss appropriate proceduralist and setting requirements to support the administration of the drug; and
- discuss the level of concern for immune-related adverse reactions and appropriate mitigation and monitoring strategies.